» Articles » PMID: 22434243

Complete Pathologic Response After Combined Modality Treatment for Rectal Cancer and Long-term Survival: a Meta-analysis

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2012 Mar 22
PMID 22434243
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Complete pathologic response (CPR) after neoadjuvant chemoradiotherapy (combined modality treatment, CMT) for rectal cancer seems associated with improved survival compared to partial or no response (NPR). However, previous reports have been limited by small sample size and single-institution design.

Methods: A systematic literature review was conducted to detect studies comparing long-term results of patients with CPR and NPR after CMT for rectal cancer. Variables were pooled only if evaluated by 3 or more studies. Study end points included rates of CPR, local recurrence (LR), distant recurrence (DR), 5-year overall survival (OS), and disease-free survival (DFS).

Results: Twelve studies (1,913 patients) with rectal cancer treated with CMT were included. CPR was observed in 300 patients (15.6%). CPR and NPR patient groups were similar with respect to age, sex, tumor size, distance of tumor from the anus, and stage of disease before treatment. Median follow-up ranged from 23 to 46 months. CPR patients had lower rates of LR [0.7% vs. 2.6%; odds ratio (OR) 0.45, 95% confidence interval (CI) 0.22-0.90, P = 0.03], DR (5.3% vs. 24.1%; OR 0.15, 95% CI 0.07-0.31, P = 0.0001), and simultaneous LR + DR (0.7% vs. 4.8%; OR 0.32, 95% CI 0.13-0.79, P = 0.01). OS was 92.9% for CPR versus 73.4% for NPR (OR 3.6, 95% CI 1.84-7.22, P = 0.002), and DFS was 86.9% versus 63.9% (OR 3.53, 95% CI 1.62-7.72, P = 0.002).

Conclusions: CPR after CMT for rectal cancer is associated with improved local and distal control as well as better OS and DFS.

Citing Articles

Nonoperative management of rectal cancer.

Williams H, Lee C, Garcia-Aguilar J Front Oncol. 2024; 14:1477510.

PMID: 39711959 PMC: 11659252. DOI: 10.3389/fonc.2024.1477510.


Baseline MRI predictors of successful organ preservation in the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial.

Williams H, Yuval J, Verheij F, Miranda J, Lin S, Omer D Br J Surg. 2024; 111(9).

PMID: 39319400 PMC: 11422670. DOI: 10.1093/bjs/znae246.


Impact of adjuvant chemotherapy on survival after pathological complete response in rectal cancer: a meta-analysis of 31,558 patients.

de Moraes F, Kelly F, Cavalcanti Souza M, Burbano R Int J Colorectal Dis. 2024; 39(1):96.

PMID: 38913175 PMC: 11196358. DOI: 10.1007/s00384-024-04668-x.


Future direction of total neoadjuvant therapy for locally advanced rectal cancer.

Kagawa Y, Smith J, Fokas E, Watanabe J, Cercek A, Greten F Nat Rev Gastroenterol Hepatol. 2024; 21(6):444-455.

PMID: 38485756 PMC: 11588332. DOI: 10.1038/s41575-024-00900-9.


Effect of adjuvant chemotherapy on the oncological outcome of rectal cancer patients with pathological complete response.

Yang J, Deng Q, Cheng Y, Fu Z, Wu X World J Surg Oncol. 2024; 22(1):31.

PMID: 38273352 PMC: 10809453. DOI: 10.1186/s12957-024-03300-0.